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Abstract
Background: Isoproterenol-induced cardiac hypertrophy in mice has been used in a number of
studies to model human cardiac disease. In this study, we compared the transcriptional response
of the heart in this model to other animal models of heart failure, as well as to the transcriptional
response of human hearts suffering heart failure.
Results: We performed microarray analyses on RNA from mice with isoproterenol-induced
cardiac hypertrophy and mice with exercise-induced physiological hypertrophy and identified 865
and 2,534 genes that were significantly altered in pathological and physiological cardiac hypertrophy
models, respectively. We compared our results to 18 different microarray data sets (318 individual
arrays) representing various other animal models and four human cardiac diseases and identified a
canonical set of 64 genes that are generally altered in failing hearts. We also produced a pairwise
similarity matrix to illustrate relatedness of animal models with human heart disease and identified
ischemia as the human condition that most resembles isoproterenol treatment.
Conclusion: The overall patterns of gene expression are consistent with observed structural and
molecular differences between normal and maladaptive cardiac hypertrophy and support a role for
the immune system (or immune cell infiltration) in the pathology of stress-induced hypertrophy.
Cross-study comparisons such as the results presented here provide targets for further research
of cardiac disease that might generally apply to maladaptive cardiac stresses and are also a means
of identifying which animal models best recapitulate human disease at the transcriptional level.
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Background
Physiological increase in cardiac muscle mass occurs nor-
mally during development, during pregnancy, and in
response to sustained exercise [1]. Conversely, pathologi-
cal cardiac hypertrophy is an adaptive response to
increased pressure load, such as with hypertension or in
the setting of aortic stenosis, or it may be associated with
an inherited disease characterized by thickening of the left
ventricle and disarray of myocytes [2]. Moreover, regional
hypertrophy can result as a consequence of myocardial
infarction in response to ischemic heart failure. Cardiac
failure remains a major source of human morbidity and
mortality in the United States [3]. The disease has multi-
ple specific etiologies, and much research has been per-
formed to elucidate some of the multiple molecular
pathways important in the development of myocardial
failure [4,5]. Many animal models of cardiac failure have
been devised, and they have played an important role in
understanding this complicated disease [6]. However, in
many cases the specific method of inducing heart failure
in animals does not obviously correlate with common
human diseases [7].
For example, some of the animal models of heart failure
are induced by pharmacologic agents to induce a direct
cardiomyopathy; however, it is relatively rare for the
human heart to be injured through such a mechanism [7].
Even the surgical occlusion of a coronary artery to induce
acute ischemia of the animal heart does not precisely
model the more common chronic ischemia that charac-
terizes the failing human myocardium [8]. Although crea-
tion of a pressure overloaded heart by aortic banding
might very closely model the pressure overloaded human
heart, such as might be seen in aortic valvular disease, it is
likely that there are significant differences in myocardial
response to acute pressure load induced in the animal
when compared to the more chronic human situation.
Therefore, it is difficult to know which animal models best
exemplify particular types of heart failure in humans.
Genetic expression array analysis allows the characteriza-
tion of tissue by assessing the expression patterns of thou-
sands of genes. Such investigations of diseased human
myocardium have been used to elucidate which molecu-
lar pathways are altered in particular etiologies of heart
failure [9,10]. In some cases, the differences in genetic
expression patterns elucidated by microarray analysis are
significant enough for clustering algorithms to distinguish
different categories of human heart failure. We hypothe-
sized that the sensitivity of this approach will allow us to
determine how closely a common animal model of car-
diac failure recapitulates the genetic milieu of the human
disease.
We induced cardiac hypertrophy in mice using isoproter-
enol, which has been shown to induce significant cardiac
dysfunction associated with a high mortality rate (up to
80%) [7]. We subjected the myocardium to genetic
expression array analysis. Genes demonstrating altered
expression compared to normal control myocardium and
myocardium that was hypertrophied following an exer-
cise regimen were compared to various other animal mod-
els of cardiac hypertrophy (e.g., aortic banding, hormone
treatment, and high salt diet) and also human diseased
myocardial expression data obtained from publicly avail-
able databases. We reasoned that microarray genetic
expression analysis of a murine heart failure model might
exhibit similarities at the genetic expression level with
some category of human disease, and would therefore
help determine which animal models correlate most pre-
cisely with particular human diseases.
Results
Analysis of pathological and physiological cardiac 
hypertrophy mouse models
Isoproteronol (ISO) administration and chronic exercise
training successfully created cardiac hypertrophy in exper-
imental animals. As shown in Fig. 1A, heart weight/body
weight ratios increased significantly (p values > 0.01, n =
6) for both the ISO-treated (6.7 ± 0.85 mg/g) and exer-
cised mice (5.8 ± 0.40 mg/g), compared to sedentary ani-
mals (4.5 ± 0.31 mg/g). However, the increase in heart
weight was much more pronounced for mice with ISO-
induced cardiac hypertrophy than for exercised mice. Sim-
ilar results were obtained when heart weight/tibia length
ratios were compared (7.1 ± 0.32 mg/mm for sedentary
mice versus 10.8 ± 1.1 mg/mm and 7.9 ± 0.41 mg/mm for
ISO-treated and exercised mice, respectively, p value <
0.01, n = 6). Hearts were also visibly larger, particularly
after ISO-treatment, as determined by examination of
H&E stained cryosections (Fig. 1B-D). While both ISO
treatment and exercise induced enlargement of the heart,
only the pathological hypertrophy model resulted in an
increased heart rate (745 ± 15 beats/min before ISO treat-
ment and 821 ± 16 beats/min after ISO-treatment, p value
0.02, n = 4; Fig. 2A). This finding may be related to treat-
ment with the beta-agonist isoproterenol, and may not be
unique to myocardial hypertrophy. Exercised mice, on the
other hand, experienced a profound reduction in heart
rate (754 ± 19 beats/min before exercise and 665 ± 13
after swimming, p value 0.002, n = 6; Fig. 2A) that was evi-
dent within the first 10 days of the swimming regimen
(Fig. 2B).
To determine whether the increase in heart size was due to
increased myocyte size or increased numbers of cardiomy-
ocytes, we quantified cell cross-sectional area in H&E
stained heart cryosections. Each cell examined had a circu-
larity (height/width) = 0.90, and > 400 cells were meas-
ured for each sample type (i.e., sedentary, exercised, and
ISO-treated). As expected, myocyte cross-sectional area
was significantly increased in mice treated with ISO, com-BMC Physiology 2009, 9:23 http://www.biomedcentral.com/1472-6793/9/23
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pared to sedentary control mice (Fig. 3A), and cardiomy-
ocytes generally appeared thicker in ISO-treated (Fig. 3C)
than in sedentary (Fig. 3B) mouse hearts, when examined
individually. Cardiomyocytes from exercised hearts were
also larger than those from sedentary mice (Fig. 3A),
although the increase in size was less dramatic (Fig. 3D),
compared to ISO-treated mice. We also assessed the levels
of fibrosis and apoptosis in sedentary, exercised, and ISO-
ISO-treatment and exercise induce enlargement of mouse hearts Figure 1
ISO-treatment and exercise induce enlargement of mouse hearts. Top - Heart Weight to Body Weight ratios (HW/
BW) for sedentary, ISO-treated or exercised mice. Values are represented as mean ± S.E.M of all mice (8-week old C57BL/6J 
males). There were 6 mice each in the sedentary group, ISO group, and exercised group. The asterisk denotes statistical signif-
icance based on Student's t test for ISO-treated or exercised mice compared to sedentary controls (p value < 0.01). Bottom- 
Representative histological coronal sections of hearts of sedentary control (A), ISO-treated (B), and exercised (C) C57BL/6J 
mice. As shown, ISO-treated and exercised mice exhibited enlarged heart masses compared to sedentary mice.
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Heart rate is increased under ISO treatment, but reduced under exercise training Figure 2
Heart rate is increased under ISO treatment, but reduced under exercise training. A) Comparison of heart rates 
in sedentary, ISO-treated, and exercised mice. Heart rates were measured before the experiment and on the day of sacrifice 
(for ISO-treated) or throughout the experiment (for exercised mice). Each heart rate is the average of at least three measure-
ments from rested mice (i.e., swimming mice heart rates were taken in the morning before exercise). Asterisk indicates statis-
tical significance when compared to sedentary control mice, based on one way ANOVA (p value = 0.008, n = 4 and p value = 
0.007, n = 6 for ISO and swim mice, respectively). B) Heart rates taken at various time intervals are indicated by bars (mean ± 
S.E.M), with beats per minute given on the left ordinate. Minutes swam (twice per day) with 5 min/day increases are shown as 
a line of interconnected points, with minutes per training session displayed on the right ordinate.
600
650
700
750
800
850
Sedentary ISO Swim
H
e
a
r
t
 
R
a
t
e
 
(
b
e
a
t
s
/
m
i
n
)
Before
After
0
100
200
300
400
500
600
700
800
900
51 0 1 5 Day
B
e
a
t
s
 
p
e
r
 
m
i
n
 
0
10
20
30
40
50
60
70
80
90
100
T
i
m
e
 
(
m
i
n
)
B 
*
*
A BMC Physiology 2009, 9:23 http://www.biomedcentral.com/1472-6793/9/23
Page 5 of 22
(page number not for citation purposes)
treated hearts (Fig. 4). As shown by H&E and trichrome
staining, there was significant fibrosis detected in ISO-
treated hearts (Fig. 4B and 4E) that was not observed in
sedentary (Fig. 4A and 4D) or exercised (Fig. 4C and 4F)
mouse hearts. Conversely, there was no evidence of apop-
tosis in any of the experimental groups apart from the
positive control (mouse thymus), as measured by TUNEL
assay (Fig. 4G-I). Considered together, these data indi-
cated that the two models induced the desired effects:
maladaptive and beneficial increases in heart mass repre-
senting pathological and physiological hypertrophy,
respectively.
ISO-treatment and exercise induce enlargement of cardiomyocytes Figure 3
ISO-treatment and exercise induce enlargement of cardiomyocytes. A) 2-dimensional cell surface area of stained 
cardiomyocytes was measured using ImageJ software. At least 5 images were taken of the left-ventricle of three different hearts 
(for each group). Bars represent mean ± S.E.M of at least 400 cells. Asterisks indicate statistical significance after application of 
one-way ANOVA (p value < 0.0001). H&E stained sections of the left ventricle of a representative sedentary (B), ISO-treated 
(C), and exercised (D) mouse are also shown. Black scale bar = 60 μm.
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Expression profiles of ISO-treated and swim-exercised 
mice
To assess and compare the global transcriptional profiles
of mice with pathological and physiological cardiac
hypertrophy, we performed gene expression microarray
analysis of RNA from the left ventricles of ISO-treated
mice, mice that were exercise trained, and sedentary con-
trol animals. The experiments were performed in tripli-
cate, and a separate microarray ran for each individual
mouse heart. A gene was considered as differentially
expressed if the fold-change was at least 1.5, the Ben-
jamini and Hochberg-corrected (B-H) p value was less
than 0.05, and the alteration occurred for each of the 9
possible pairwise comparisons (i.e., each of the 3 controls
versus each of the 3 experiments). Based on these criteria,
there was a total of 940 probe sets representing 865 differ-
ent genes (634 up-regulated and 231 down-regulated)
that were significantly and reproducibly altered between
control and ISO-treated animals. The transcriptional pro-
file of mice that were swam twice daily, on the other hand,
was more profoundly affected, with 2,670 probe sets rep-
resenting 2,534 genes altered (936 up-regulated and
1,598 down-regulated), compared to sedentary control
animals. Eight genes were selected for verification by real-
time reverse transcriptase polymerase chain reaction (RT-
PCR), the results of which validated the microarray analy-
sis (Table 1). The entire list of genes altered in response to
exercise or ISO treatment is provided as Additional File 1,
and examples are shown in Fig. 5, in which genes with
similar expression patterns clustered together using Clus-
ter/Treeview software programs to analyze Z-score trans-
formed signal intensity values from all nine arrays.
Based on pathway analysis results using Ingenuity Path-
way Analysis software, the top associated signalling net-
work functions in mice treated with ISO were
cardiovascular disease, free radical scavenging, and molec-
ular transport (28 genes out of 39 network molecules),
whereas the top associated network functions for mice
that exercised were gene expression, cell morphology, and
cell-cell signalling and interaction (35 genes out of 40 net-
work molecules). Interestingly, the most over-represented
molecular functions after multiple hypothesis testing cor-
rection were cell death for ISO-treated mice (188 mole-
cules, B-H p values 6.1 × 10-20 to 6.6 × 10-4) and cellular
growth and proliferation for mice that were swam (462
molecules, B-H p values 4.5 × 10-20 to 5.0 × 10-2). The
top physiological functions in ISO-treated mice were
immune system development and function (121 mole-
cules, B-H p values 1.9 × 10-9 to 6.6 × 10-4) and immune
response (113 molecules, B-H p values 5.7 × 10-9 to 6.6 ×
10-4), whereas the most over-represented physiological
functions in exercised mice were organismal survival (175
molecules, B-H p values 1.0 × 10-11 to 5.0 × 10-2) and
organ development (146 molecules, B-H p values 2.0 ×
10-6 to 1.6 × 10-3). Molecular pathway analysis also indi-
cated that cardiovascular system development and func-
tion (149 molecules, B-H p values 7.2 × 10-6 to 4.1 × 10-
3) was a major physiological function associated with
genes altered in exercised mice, but not in ISO-treated ani-
mals. The top canonical signalling pathways in ISO-
treated mice included acute phase response (24 mole-
cules, B-H p value 4.7 × 10-7), fibrosis (14 molecules, B-
H p value 5.5 × 10-6), NRF2-mediated oxidative stress
response (16 molecules, B-H p value 1.2 × 10-2), and
VEGF signalling (10 molecules, B-H p value 1.2 × 10-2).
The most over-represented signalling pathways identified
by Ingenuity for the list of genes altered in response to
exercise were PI3K/AKT (37 molecules, B-H p value 8.6 ×
10-9), ERK/MAPK (44 molecules, B-H p value 9.7 × 10-7),
integrin (45 molecules, B-H p value 1.7 × 10-6), PPAR sig-
nalling (27 molecules, B-H p value 1.8 × 10-6), and
PPARα/RXRα activation (40 molecules, B-H p value 2.3 ×
10-6).
The vast majority of genes altered in response to ISO treat-
ment or swimming were specific to the condition (that is,
there was relatively little overlap in the types of genes
ISO treatment induces fibrosis but not apoptosis in mouse  hearts Figure 4
ISO treatment induces fibrosis but not apoptosis in 
mouse hearts. H&E stained sections of the left ventricle of 
a representative sedentary (A), ISO-treated (B), and exer-
cised (C) mouse are shown. Similar sections were stained 
with Masson trichrome to assess fibrosis in sedentary (D), 
ISO-treated (E), and exercised (F) mouse hearts. TUNEL 
staining indicated that there was no detectable apoptosis in 
these same hearts. A positive control (mouse thymus) for 
TUNEL staining is shown in panel G, and representative ISO-
treated and exercised mouse hearts (left ventricles) are 
shown in panels H and I, respectively. TUNEL staining of sed-
entary mouse hearts was similar to ISO-treated and exer-
cised mice (no apoptosis detected; data not shown). Black 
scale bar = 120 μm.
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altered under these two conditions.) However, there were
159 genes that were altered by both types of cardiac hyper-
trophy, whose functions were mainly related to immune
response, particularly antigen presentation (14 molecules,
B-H p values 2.1 × 10-5 to 3.1 × 10-2) and hematological
system development and function (29 molecules, B-H p
values 1.4 × 10-6 to 4.0 × 10-2). Of these 159 overlapping
genes, 139 were altered in the same direction in patholog-
ical and physiological cardiac hypertrophy models (i.e.,
42 up-regulated and 97 down-regulated in ISO-treated
and exercised trained mice, compared to sedentary con-
trol animals). Conversely, there were 20 genes that were
altered in each condition in the opposite direction (e.g.,
up-regulated in ISO-treated mice and down-regulated in
exercised animals) (Table 2).
Comparison of physiological and pathological cardiac 
hypertrophy across various studies and models
To compare our results to previously published studies,
we obtained all available data files from the GEO website
for experiments previously conducted to measure tran-
scriptional responses to exercise-induced cardiac hyper-
trophy or experimentally-induced pathological
hypertrophy. Exercise models included swimming mice
and various rat strains trained on treadmills for various
time intervals [11-17]. Experimentally-induced patholog-
ical cardiac hypertrophy models causing significant car-
diac dysfunction and varying degrees of cardiac failure
and mortality included familial hypertrophic cardiomy-
opathy (FHC) in mice (achieved via an R403Q missense
mutation in one allele of the α-myosin heavy-chain gene,
αMHC403/+ [18]), myocardial infarction in mice [19], aor-
tic banding (i.e., transverse aortic constriction) [20-24] in
various strains of rats and mice, arteriovenous shunt,
myocardial infarction, and hormone (angiotensin II and
3,5-diidothyroproionic acid) treatments in rats [22], as
well as high salt diet in Dahl rats [14]. We also obtained
microarray data comparing "normal" human hearts (non-
diseased samples obtained during autopsy) to heart sam-
ples collected during heart transplant surgeries from
patients with end-stage heart failure (idiopathic, ischemic,
aortic stenosis, and congenital) [25]. For Affymetrix data
in which CEL files were available, data were RMA normal-
ized, Student's t test was performed, and each group was
averaged in order to obtain a fold-change value (using
GeneSifter software). This less stringent data analysis
approach was intended to make the results more compa-
rable across microarray platforms and studies and mini-
mize the level of false negatives. For data provided only in
text form, data were assumed to be pre-normalized by the
previous researchers (per GEO submission requirements),
and Student's t test and fold-change were calculated
directly from the provided data. For two of the previous
studies [16,17], raw data were not publicly available; we
therefore used the gene list provided in the publications.
All studies, including overall comparative results, are
listed in Table 3.
As expected, there was a great deal of variation in the total
numbers of altered genes between the various studies,
array platforms, disease models, strains, and time frames.
It is perhaps worth noting, however, that our intention
was not to highlight potential differences in experimental
technique between groups or compare the potential value
of one disease model over another. Rather, we hoped to
identify a set of genes that would represent those canoni-
cal changes that are captured most frequently under vari-
ous experimental conditions and thus might represent
consistent genetic expression alterations that might be
applicable to the study of the human end-stage failing
heart. We therefore grouped study types together and con-
sidered the most profound alteration (i.e. largest fold-
change in magnitude) as representative for that group.
Groups were chosen based on model type and animal,
while more detailed parameters (e.g., strain, time frame,
experimental details) were not considered. This resulted
in 14 distinct experimental groups with relevant cardiac
expression data: 2 exercise models (swimming mice and
rats trained on treadmills), 8 pathological models (mice
with aortic banding and myocardial infarction, αMHC403/
+ mice, rats with aortic banding, drug-induced cardiac
hypertrophy, myocardial infarction, arteriovenous shunt,
and high salt diet), and 4 human diseases (idiopathic,
ischemic, aortic stenosis, and congenital cardiac hypertro-
phy).
Based on our analyses and comparison methods, there
were 59 genes that were altered in response to exercise in
our study and in swimming mice from other studies or
treadmill-exercised rats (Table 4). However, there were
only two genes (Cd74 and Col3a1) that were altered in our
study and in both mice and rats irrespective of the model
Table 1: Verification of microarray data by real-time RT-PCR
Gene ID Gene Symbol Array Real-time
ISO Swim ISO Swim
FC
NM_007707 SOCS3 5.9 ND 2.0 ND
M65143 LOX* 7.5 ND 8.0 -2.5
NM_133249 Ppargc1b -2.8 ND -1.9 ND
AK018378 A d r b 1 - 1 . 7N D- 1 . 9N D
NM_007392 A c t a 2 - 3 . 7- 3 . 2- 5 . 7- 6 . 5
NM_010809 Mmp3 6.0 ND 3.3 ND
BI78842 Timp4 5.4 3.6 4.9 10.6
AK020831 Adamtsl2 2.0 ND 2.3 ND
Asterisk (*) indicates that a related gene (Loxl1, AF357006) was 
down-regulated 2.6-fold in exercised mice, compared to sedentary 
control animals. ND = no significant difference detected. FC = fold-
change. Fold-change values shown are representative of 3 
independent experiments.BMC Physiology 2009, 9:23 http://www.biomedcentral.com/1472-6793/9/23
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ISO-treatment an exercise induce differential transcriptional profiles Figure 5
ISO-treatment an exercise induce differential transcriptional profiles. Hierarchical clustering of genes altered in 
mouse hearts in response to exercise (A) or ISO treatment (B). Bright red indicates the highest normalized signal values, 
bright green represents the lowest signal values, and black represents median signal values. The heat map was produced by 
clustering normalized signal values (exported from GeneSifter) using Cluster/Treeview software. Abbreviations used are as fol-
lows: Swim = exercised mice, ISO = isoproterenol-treated mice and Con = sedentary control mice. Replicates samples are 
indicated by number (1 -3). Only subsets of each clustering result are shown, with gene symbols provided to the right of each 
set of array probes (i.e., each row represents one gene, and each column represents an individual experimental sample).
ABBMC Physiology 2009, 9:23 http://www.biomedcentral.com/1472-6793/9/23
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type or study. Col3a1 was of particular interest, because it
was down-regulated in response to exercise in mice (1.6,
3.1-fold) and rats (1.8-fold) but up-regulated in most
pathological cardiac hypertrophy models, including
αMHC403/+ mice (2.2-fold), aortic binding in mice (3.1-
fold) and rats (1.6-fold), arteriovenous shunt (1.7-fold),
myocardial infarction (2.5-fold), and idiopathic and
ischemic cardiac hypertrophy in humans (1.5- and 2.0-
fold, respectively). Interestingly, Col3a1 was down-regu-
lated (2.9-fold) in Dahl rats fed a high salt diet, but only
at the latest time point tested (15 wk). There were two
exercise-induced genes that differed in directionality
depending upon which type of rodent or experimental
model was used. Timp3 was up-regulated in swimming
mice but down-regulated in exercised rats. Conversely, dbp
was up-regulated in rats and down-regulated in mice
(Table 4). Interestingly, 8 genes, including dbp, that were
represented by more than one "polony" (analogous to an
array probe set), were detected as up-regulated and down-
regulated by PMAGE in αMHC403/+ mice, compared to
wild-type littermates (Table 4). This result could reflect
the greater sensitivity of PMAGE to detect transcripts
present at low abundance (<1 copy/cell), transcript iso-
form differences, or detection of technique-specific arti-
facts resulting from the use of fold-change as a filtering
criterion.
Consistent with molecular signalling events known to
occur under conditions of physiological cardiac hypertro-
phy, there were three PI3K/AKT signalling pathway mole-
cules (Gsk3b,  Nfkbia, and Ppp2r1a) altered in exercised
mice and rats. Moreover, the PI3K/AKT was statistically
over-represented in the 57 genes consistently altered
across experimental models, based on Ingenuity pathway
analysis (B-H p value 2.2 × 10-3). Over-represented cellu-
lar processes included cell death (18 molecules, mainly
down-regulated, B-H p values 2.2 × 10-5 to 1.8 × 10-2), cel-
lular assembly and organization (14 molecules, B-H p val-
ues 3.8 × 10-5 to 1.8 × 10-2), molecular transport (14
molecules, B-H p values 1.7 × 10-4 to 1.7 × 10-2), and cel-
lular development (13 molecules, B-H p values 3.5 × 10-4
to 1.8 × 10-2). Immune response (10 molecules, B-H p val-
ues 1.7 × 10-4 to 1.8 × 10-2) was the most significantly
over-represented physiological function.
Table 2: Genes with overlapping but opposite alteration in ISO-treated and exercise mouse hearts
Gene ID Gene Name Gene Symbol Function ISO Swim
FC p FC p
BE133150 ESTs NA Unknown 2.0 0.002 -2.1 0.011
BC019553 cDNA NA Unknown 2.6 0.002 -2.9 0.002
BI180630 ESTs NA Unknown 2.0 0.007 -2.1 0.007
BM234799 cDNA NA Actin cytoskeleton organization 1.7 0.009 -2.0 0.006
BB283973 cDNA NA Unknown -3.1 0.010 2.4 0.020
AW537707 Actin, beta, cytoplasmic Actb Non-muscle cytoskeletal constituent -3.0 0.009 1.8 0.009
NM_007398 Adenosine deaminase Ada Smooth muscle contraction; immune 
response
2.2 0.004 -1.9 0.005
AV229424 Collagen, type V, alpha 2 Col5a2 Extracellular matrix structural constituent 2.2 0.022 -2.2 0.005
NM_010188 Fc receptor, IgG, low affinity III Fcgr3 Antigen processing and presentation via MHC 
class I
2.1 0.006 -1.6 0.003
BC004724 Fibronectin 1 Fn1 Acute-phase response; cell-matrix adhesion 2.3 0.020 -1.7 0.005
AK012898 Glycine/arginine rich protein 1 Grrp1 Unknown 3.5 0.005 -2.3 0.005
BB269715 Hypoxia inducible factor 1, alpha 
subunit
Hif1a Angiogenesis; neural crest cell migration; 
response to hypoxia
-1.9 0.002 2.0 0.002
BE995678 Heat shock protein 90, beta (Grp94), 
member 1
Hsp90b1 Stress response -8.4 0.009 3.4 0.014
NM_030127 HtrA serine peptidase 3 Htra3 Regulation of cell growth 1.8 0.006 -2.2 0.006
BC003209 Integrator complex subunit 3 Ints3 snRNA processing 2.2 0.006 -2.7 0.006
NM_008606 Matrix metallopeptidase 11 Mmp11 Collagen catabolism 2.3 0.013 -1.9 0.006
NM_010929 Notch gene homolog 4 Notch4 Patterning of blood vessels; cell fate 
determination
2.0 0.005 -2.0 0.006
AK013448 Protein phosphatase 1, regulatory 
(inhibitor) subunit 14c
Ppp1r14c Signal transduction -2.8 0.002 2.2 0.003
BE137091 Regulatory solute carrier protein, 
family 1, member 1
Rsc1a1 Regulation of protein transport and 
modification
2.0 0.005 -1.8 0.006
NM_011581 Thrombospondin 2 Thbs2 Inhibits microvascular endothelial cell 
proliferation; cell adhesion; wound repair
2.2 0.002 -1.7 0.004
FC = fold-change. Dash ("-") before number indicates down-regulation, compared to appropriate controls. NA - not applicable, where a gene 
without a gene symbol was identified as altered in expression (i.e., cDNA, EST, or gene encoding a hypothetical protein). ISO and Swim = Control 
mice versus isoproeteronol-treated or exercised mice, respectively. Gene functions were obtained from Ingenuity pathway analysis software, 
supplemented with information obtained from the NCBI and Stanford SOURCE search databases.BMC Physiology 2009, 9:23 http://www.biomedcentral.com/1472-6793/9/23
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Table 3: Comparison of Multiple Cardiac Hypertrophy Studies
Study Model Array Samples Time course n = Sig Genes Common Genes
Swim ISO
Physiological CH Models
This Study C57BL/6 mice Affy 430 2.0 Control 8 wk 3 2,351 - 139/20
Swim 3
GSE77a [11] FVB mice Affy U74Av2 Control 10 min 3 141 2/26 5/6
Swim 3
Swim 2.5 day 3 32 10/2 4/3
Swim 1 wk 3 41 11/3 8/2
Swim 2 wk 3 77 9/7 10/9
Swim 3 wk 3 51 2/1 8/3
Control 4 wk 3 68 14/14 6/5
Swim 3
Control 4 wk/1 wk 3 13 2/1 1/1
Swim/Rest 3
GSE739b [12] Wistar rats Affy U34A Sedentary 7 wk 6 39 1/2 7/1
Treadmill 6
GSE7640a [13] Rats [d] Affy 230 2.0 Sedentary 10 wk 10 18 1/0 1/0
Mild exercise 10
GSE776a [14] Dahl rats Affy U34A Sedentary 3 wk 3 293 20/40 7/18
Treadmill 3
Sedentary 6 wk 3 282 12/36 8/14
Treadmill 3
GSE9445a [15] N:NIH LCR rats Affy 230 2.0 Sedentary 8 wk 4 19 0/1 2/0
Treadmill 4
N:NIH HCR rats Sedentary 4 42 1/1 2/1
Treadmill 4
Diffee et alc [16] Sprague-Dawley rats Affy U34A Sedentary 11 wk 9 27 1/1 1/4
Treadmill 9
Iemitsu et alc [17] Atlas 3.8I Sedentary 8 wk 8 75 4/5 1/1
Treadmill 8
Pathological CH Models
This Study C57BL/6 mice Affy 430 2.0 Control 10 day 3 808 139/20 -
ISO-treated 3
Kim et alc [31] FHC
Mice [d]
PMAGE Wild-type 8 wk 4-5 706 215/272 121/79
αMHC403/+ 25 wk
GSE1621a [20] FVB mice Affy U74av2 Sham 48 hr 4 15 0/3 4/1
TAC 5
Sham 10 day 4 106 9/30 10/5
TAC 5
Sham 3 wk 4 95 8/21 13/3
TAC 5
GSE2459b [21] FVB mice Affy U74av2 Sham 10 wk 9 307 14/24 14/7
TAC 6
GSE1145a [25] Humans Affy 133 2.0 Normal N/A 11 - - -
Idiopathic dilated 15 2,480 124/200 35/99
Ischemic 11 1,214 66/74 38/45
Affy U95A Normal 4 - - -
Aortic stenosis 7 57 5/4 4/2
Congenital 6 354 10/50 1/18
GSE738b [22] Wistar rats Affy U34A Sham 3 wk 2 50 1/8 2/1
Shunt 2
Sham 8 wk 2 32 0/5 2/2
Shunt 2
Sham 3 wk 2 55 4/8 12/1
Myocadial infarction 4
Sham 9 wk 2 99 4/15 5/4
Myocadial infarction 4
Sham 6 wk 2 64 6/1 6/1
Aortic banding 2BMC Physiology 2009, 9:23 http://www.biomedcentral.com/1472-6793/9/23
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We used a similar approach to examine ISO-induced tran-
scriptional alterations, expecting that each gene was simi-
larly altered for at least one human disease equivalent to
be considered significant. The results of this comparison,
including fold-changes obtained from other animal mod-
els and also exercised rodents, are shown in Table 5. There
were 68 gene expression alterations (36 up-regulated and
32 down-regulated genes) that showed considerable over-
lap between model types and studies that were also simi-
larly altered in at least one of the four human diseases.
This included two traditional markers of cardiac hypertro-
phy (MHC-β and Atp1a1/SERCA). Ingenuity pathway
analysis confirmed that the most over-represented molec-
ular pathways in this canonical list of genes were cellular
growth and proliferation (22 genes, B-H p values 1.8 × 10-
7 to 6.3 × 10-3), cell-cell signalling and interaction (14
genes, B-H p values 2.4 × 10-7 to 6.3 × 10-3), cell death (20
genes, B-H p values 7.4 × 10-7 to 6.3 × 10-3), cellular move-
ment (14 genes, B-H p values 9.9 × 10-7 to 6.3 × 10-3), and
cellular development (23 genes, B-H p values 1.3 × 10-6 to
6.3 × 10-3). Twelve of the genes were specifically associ-
ated with cardiovascular system development and func-
tion (B-H p values 1.2 × 10-6 to 6.3 × 10-3).
Analysis and comparison of animal cardiac hypertrophy 
models to human cardiac disease
To identify genes that are most likely to be relevant to
human disease, we compared the microarray results from
our study along with all the previous studies listed in
Table 3 to the GSE1145 gene expression dataset (i.e.,
human idiopathic, ischemic, aortic stenosis, and congen-
ital cardiac hypertrophy). An average fold-change was cal-
culated to represent each model type (i.e. cardiac
hypertrophy induced by drug treatment, aortic banding,
myocardial infarction, shunt, high salt diet, or exercise).
Inclusion in the final list of relevant genes required that at
least one of the rodent pathological cardiac hypertrophy
models (i.e., drug, aortic banding, myocardial infarction,
shunt, or salt) exhibit an alteration in the same gene in the
same direction. Also included were genes that were altered
in the opposite direction (i.e., up-regulated in humans
and down-regulated in animals) if the alteration was
observed in at least two animal models. Finally, to elimi-
nate those genes that might be specific to just one group
of humans (or one type of cardiac hypertrophy) an alter-
ation was expected to have occurred in at least two out of
the four human diseases included.
When examined individually, there were 140, 134, 19,
and 35 genes in humans with idiopathic, ischemic, aortic
stenosis, and congenital-related cardiac hypertrophy,
respectively, that exhibited significant overlap with results
obtained from studies using animal models (data not
shown). When the four lists were compared, there were 64
genes that were significantly altered in at least two of the
human diseases that also exhibited significant overlap
(based on the aforementioned criteria) with the animal
models (Table 6). Interestingly, The most statistically sig-
nificant over-represented molecular and cellular func-
tions, based on Ingenuity Pathway Analysis software, were
cell death (23 genes, B-H p values 1.2 × 10-7 to 5.1 × 10-3),
cellular movement (22 genes, B-H p values 3.2 × 10-7 to
Sham 12 wk 2 21 2/1 3/0
Aortic banding 2
Sham 16 wk 2 101 5/6 3/2
Aortic banding 2
Sham 30 wk 2 107 5/15 10/3
Aortic banding 4
Vehicle 2 wk 2 - - -
Ang2 2 28 0/1 3/0
Dipta 2 5 0/1 0/0
GSE5500a [23] Mice [e] Affy 430 2.0 Sham 7 day 4 - 23/74 39/10
TAC 6 470
GSE12337a [24] Mice [d] Affy 430 2.0 Sham 28 day 4 - 0/8 2/0
TAC 4 12
GSE775b [19] Mice [d] Affy U74Av2 Control 1 wk 4 1,585 69/127 93/29
Myocardial infarction 3
Control 8 wk 4 698 48/34 23/14
Myocardial infarction 3
GSE776a [14] Dahl rats Affy U34 Control 3 wk 3 - 2/9 8/7
High salt diet 3 62
Control 6 wk 3 40/24 15/6
High salt diet 3 315
Control 15 wk 3 - 37/11 36/3
High salt diet 3 224
aCEL files analyzed, bText files analyzed, c Genes obtained from published article, dstrain information not provided by submitters, eC57BL6/J-FVB/N 
genetic background; Ang2 = Angiotensin II; Dipta = 3,5-diiodothyropropionic acid, FHC = familial hypertrophic cardiomyopathy
Table 3: Comparison of Multiple Cardiac Hypertrophy Studies (Continued)BMC Physiology 2009, 9:23 http://www.biomedcentral.com/1472-6793/9/23
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Table 4: Genes altered in response to exercise, grouped by function
Gene Physiological Pathological
This study Swim Tread Drug RQ MI AB Sh MI Salt Idiop Isch AS Cong
Mice Rats Mice Rats Humans
FC
Cell adhesion/migration
Acta2 -3.2 -1.9 -3.7 1.7 1.8 1.6 -2.6
Aplp2 -1.7 -2.1 +/-
Lmo7 1.8 1.7 -8.2 -1.5 -1.5
Ap2s1 -2 -1.6 1.7
Cellular assembly and organization
Itga7 -2.8 -1.6 -1.5
Nfia 1.9 1.9 -1.6 -2.3
Sorbs1 11.3 2.1 d -6.7
Tmsb10 -2.6 -1.5 2.8 2.3 -2.1
Cell death
Aes -2.2 -1.9 +/- -5.2 1.6 1.8
Akap1 -1.9 -1.7 -2.1 -2.6 -7.3 1.9
Cd74 -3.8 -2.1 -1.7 -3.1 1.7 1.5
Cd99 -2.1 -1.6 -3.2
Crp 2.3 1.7 -2
Cyb5r3 -2.3 -1.6 i
Fbn1 -2.8 -1.5 2.9 2.2 1.5
Gsk3b 6.2 1.6 -1.6 -2.2 -1.7
H2-D1 -3.3 -1.6
Kcnk3 -2.6 -2 d -13.5 2.3 -1.8
Lamb2 -2.3 -1.7 -3.3
Mapt -2.2 -1.7 -15.4 2.4 2.8
Nfkbia -2.7 -1.6 1.5 -1.9
Nme3 -2 -1.5 -3
Nupr1 -2.5 -1.5 3.3 3.6
Pitpna -1.8 -1.5 -1.8
Ppargc1a 7 2.5 -7.3
Ppp2r1a -1.9 -2.9 +/- 2.3
Tfrc -4.2 -1.5 -12.3 10.1 1.8 -1.6 -1.7
Cell growth and development
Dbp -2.8 -1.6 2.2 +/- -1.9 -2.4
Gna12 -2.4 -1.5 1.5
Ltbp4 -3 -1.7 i 1.6 1.7
Nedd8 -1.7 -1.6
Pctk1 -1.7 -1.6 9
Heart contraction
Dmpk -3.2 -1.6 -5.2
MHC-β 11.5 3.4 2.7 4.5 2.6 1.9 2.3 1.6* 2.5*
Immune functions
C1qa -2.1 -1.5 3.4 1.7 1.7
C1qc -2.4 -1.5 1.7 1.7
Col1a1 -4.7 -1.6 +/- 3.4 2.4 1.7 2 -2.6 1.6 1.8 1.5
Col3a1 -3.1 -1.6 -1.8 2.2 4.9 3.1 1.6 1.7 2.5 -2.9 1.5 2
Fabp4 2.7 1.7 -1.7
H2-Aa -3 -1.6 -3.9 1.9
H2-K1 -2.9 -1.7 6
Psmb8 -2.5 -1.6 2.3
Extracellular matrix organization
Adam19 -2.3 -1.6 1.5
Col15a1 -3.2 -1.6 -2.8 +/- 2.1 2.3 -2.7
Matr3 2.1 1.6 1.7
Timp3 4.5 1.6 -1.5 -1.5
Other or unknown
Ccdc53 -1.9 -1.5
Ccdc56 -2.1 -2.1 -2.6 2.2BMC Physiology 2009, 9:23 http://www.biomedcentral.com/1472-6793/9/23
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5.1 × 10-3), cellular growth and proliferation (30 genes, B-
H p values 1.1 × 10-6 to 5.1 × 10-3), cell-to-cell signalling
and interaction (21 genes, b-H p values 8.4 × 10-6 to 5.1 ×
10-3), and cell cycle (15 genes, B-H p values 9.3 × 10-6 to
5.1 × 10-3). The most over-represented physiological func-
tions were tissue morphology (18 genes, B-H p values 1.1
× 10-5 to 5.1 × 10-3), cardiovascular system development
and function (13 genes, B-H p values 1.4 × 10-5 to 5.1 × 10-
3), connective tissue development and function (10 genes,
B-H p values 1.4 × 10-5 to 5.1 × 10-3), skeletal and muscu-
lar system development and function (16 genes, B-H p
values 1.8 × 10-5 to 5.1 × 10-3), and organismal develop-
ment (9 genes, B-H p values 2.6 × 10-5 to 5.1 × 10-3). The
most profoundly affected signalling network, involving
23 out of the 64 genes broadly associated with animal car-
diac hypertrophy models and the human disease indi-
cated that TGF-β in particular might be generally involved
in the dysfunctional heart (Fig. 6).
To compare animal models and human disease data sets,
we generated a similarity matrix based on average fold-
change observed for each disease type compared to its
appropriate study control for all overlapping genes (i.e.,
genes represented on all array platforms for both rodents
and humans). The two data sets for which raw data were
unavailable were excluded. Similarity was measured as the
number of genes in common with fold-changes that
occurred in the same direction (e.g., up-regulated com-
pared to control samples) with a magnitude of at least 1.5.
All possible pairwise comparisons were performed, and
the resulting matrix was used to create a clustering dia-
gram to illustrate which groups most closely resembled
one another (Fig. 7A). As expected, the rodent exercise
model least resembled induction of pathological cardiac
hypertrophy in animals or human cardiac disease. The
Angiotensin II, 3,5-diiodothyropropionic acid, and high
salt animal models least resembled human disease, and
ISO treatment was most similar to ischemic and idio-
pathic cardiac failure in humans. Similar results were
obtained when ontological categories of altered genes
were analyzed for each model and disease group using
Ingenuity Pathway Analysis software program (Fig. 7B).
As shown, the most common functions were related to
cellular growth and proliferation, immune-related signal-
ling/processes, and cardiovascular functions.
Discussion
A variety of methods have been used to simulate human
heart disease in animals, and a great many studies have
been conducted to examine the transcriptional profiles of
these animals, especially in conjunction with signalling
pathway perturbation or drug discovery. Few studies,
however, have attempted to coalesce these various data to
identify canonical molecular signalling pathways. A nota-
ble exception is Strom et al [22], who comprehensively
compared several different rodent models of cardiac
hypertrophy to identify a core set of genes that might gen-
erally characterize cardiac hypertrophy signalling. This
previous study, however, did not include ISO, which is
thought to induce myocardial damage via an increase in
catecholamines and subsequent imbalance of energy sup-
ply and cardiac hyperactivity [26]. ISO is mainly used as a
cardiac hypertrophy model because it is convenient and
yields rapid and reproducible results, but very little is
known regarding the precise mechanism of action of this
drug or exactly how it induces cardiomyopathy [7]. Our
laboratory previously tested an FDA-approved generic
antibiotic using the ISO model and found that physiolog-
Ell2 5 1.8 2.4 -2.2 -1.9 -1.8
Fstl1 -2 -1.6 6.6 2.8 1.8 1.9 -1.6
Gas5 -2.5 -1.7 -1.8
Kank3 -2.1 -1.7
Lipa -2.6 -1.7 -1.6
Ptrf -2.4 -1.6 +/- 1.5
Slc29a4 1.8 1.7
Snrp70 2.2 1.6 -1.6
Ssbp1 -1.7 -1.5
Tsc22d4 -2.2 -1.5 -1.9 d -2.9
Ttc3 2.4 1.6 +/- 1.5
FC = fold-change. Dash ("-") before number indicates down-regulation, compared to appropriate controls. A blank indicates that no significant 
alteration (fold change at least 1.5, p value ≤ 0.05) was observed. The asterisk indicates that a variant of MHC-β (MYH7B) was up-regulated. For 
PMAGE data, "i" and "d" indicate induction and down-regulation with 0 transcripts detected in either wild-type or αMHC403/+ mice, respectively. 
Where genes that were represented by more than one polony (analogous to a probe set) conflicted in direction (one or more up-regulated 
sequence tags and one or down-regulated sequence tags representing the same gene), "+/-" is used in place of a FC value. Gene highlighted in bold 
font was a consistent finding (down-regulated in exercised rodents and up-regulated in various pathological cardiac hypertrophy conditions). Idiop, 
Isch, AS, and Cong = idiopathic, ischemic, aortic stenosis, and congenital, respectively. "Drug" refers to isoproterenol, angiotensin II, or 3,5-
diiodothyropropionic acid treatment. Sh, MI, and AB = shunt, myocardial infarction, and aortic banding, respectively. RQ = αMHC403/+ mice, 
representing familial cardiac hypertrophy. Gene functions were obtained from Ingenuity pathway analysis software, supplemented with information 
obtained from the NCBI and Stanford SOURCE search databases. Some genes perform more than one function, but are only listed under one 
category.
Table 4: Genes altered in response to exercise, grouped by function (Continued)BMC Physiology 2009, 9:23 http://www.biomedcentral.com/1472-6793/9/23
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Table 5: Genes altered under conditions of pathological cardiac hypertrophy, grouped by function
Gene Pathological Phys
This Study RQ MI AB Sh MI Drug Salt Idiop Isch AS Cong Exercise
Mice Rats Humans Rodents
FC
Cell adhesion and migration
Aoc3 2.2 1.5
Itgbl1 2.4 1.8 1.6 2.8
Ltbp2 3.3 13.1 2 1.7 2.5
Omd 2.6 5.1 1.9 2.6 2.4
Cardiovascular functions and/or disease association
Angptl2 -2.2 1.7 -1.5 -2.3
Atp1a1 -1.9 d -4.0 1.8 2.3 -1.7 -1.6 -5.3
Ctgf 3.7 2.1 3.1 2.7 1.5 2.2 -3.5
Dcn 2.8 1.8 1.6 1.7 1.6 -1.6
Fbxw7 -1.8 -1.5
Fn1 2.3 1.9 1.8 3 1.7 1.9 1.6 -1.6 -1.6 2 2
Hif1a -1.9 1.5 -1.9 -1.5
Hyou1 -1.8 -1.9 -1.7
Kdr -1.9 7 -1.7 -1.5 2.3
Lox 10.1 24.6 3.5 1.5 2
Mef2c -2.2 -3.1 -1.6
MHC-β 2.7 4.5 2.6 1.9 2.3 1.6* 2.5*
Prox1 -1.8 -20 -1.5 -1.8 -1.6
Sfrs2 -2.7 -1.7 3.4
Thbs2 2.5 7 1.8
Cell-cell signaling
Palld -3.4 -1.9 2
Ramp1 -3 -1.6
Cellular Movement
Trak1 -2 -1.6
Tuba4a -6 -7.7 -2.8 -1.7
Tubb2a -2 1.6 -1.6
Cell cycle arrest and/or cell death
Ddit4 7 1.9 -2.2
Il17rd 1.9 1.6
Isg20l1 -1.6 -1.6 -3.6
Prmt1 -2.1 -1.8
Scn7a 2.1 -2.1 1.9
Development
Ezh1 1.9 1.8
Hopx -2.5 -18.5 -2.5 -3.1
Slc40a1 2.1 1.5 1.6 2.1 -1.7
Ttll7 4.2 1.7
Cell growth/proliferation
Brd4 -1.8 -1.6
Ccng2 3 -1.7 1.8
Cdh13 -8.3 d -6.7 -2
Clu 2.1 2.7 1.7 1.5 1.6 1.8 1.5 -1.5
Cthrc1 3.5 2.5 2.4
Egr1 -3.3 1.9 -1.7 1.8 1.6 -2.2 1.9 -2.8
Fkbp4 -2.6 -7.2 -1.6 -2.1 -1.6 -1.5
Hipk2 -2 4 -1.5 -1.6 -1.6
Hk2 -2 -6.9 -1.8 -1.7 1.5
Hsp90b1 -8.4 -1.6 -1.6
Kif1b -3.6 3 -3.6 -1.6
Mlf1 -2 -2.1 -25.2 -1.5 -2
Nox4 4.7 1.6
Pdgfd 1.9 -1.6 2.1
Plagl1 2.4 3.5 1.8 -4.2
Plcb4 1.8 1.6BMC Physiology 2009, 9:23 http://www.biomedcentral.com/1472-6793/9/23
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ical and microarray data supported the use of doxycycline
as an efficacious treatment for ISO-induced cardiac hyper-
trophy [27]. These results were reproducible using trans-
verse aortic banding and post-myocardial infarction
hypertrophic animal models [27]; however, it is nonethe-
less important to identify the underlying molecular mech-
anisms of ISO-induced hypertrophy and correlate this
animal model with human cardiac disease.
The results of this study show that ISO induces transcrip-
tional alterations in mouse hearts that differ drastically
from those elicited by normal hypertrophy in response to
exercise training (Additional File 1). Moreover, the differ-
ential functions and pathways associated with gene
expression alterations elicited by the two types of treat-
ments are consistent with what is known about molecular
signalling events that are specific to pathological versus
physiological cardiac hypertrophy. For instance, ISO treat-
ment results in the alteration of several genes involved in
acute phase and oxidative stress response signalling,
which is associated with maladaptive cardiac remodeling
[4,5]. Conversely, swimming-induced gene expression
alterations in mouse hearts were mainly those known to
be involved in normal increases in heart mass resulting
from exercise (e.g., PI3K/AKT and ERK MAPK signalling
pathways) [2].
Based on our comparisons of our genetic expression
results and the results of others using a wide variety of
other animal models of cardiac hypertrophy, we conclude
that the transcriptional profile of ISO-treated mice most
resembles gene expression alterations induced by the
transverse aortic banding model. However, the similarity
is mainly limited to mice, with few overlapping genes
detected between ISO-treated mice and the various rat
models. A more extensive study would be required to
compare mouse and rat models in order to conclusively
determine which best mimics human cardiac disease. Our
results indicate that profound differences in gene expres-
sion patterns exist between the two types of models that
warrant further investigation.
Despite the expected variability between studies arising
from differences in animal disease models, strains, exper-
imental variations, array platforms, and species-related
differences, our results indicate that among human car-
diac diseases, ischemic-related cardiac hypertrophy most
closely resembles ISO-treatment of mice (Fig. 7). The sim-
ilarity of ISO-treatment to idiopathic heart disease sug-
gests that the majority of idiopathic patients exhibited
ischemia-associated cardiac hypertrophy and also implies
that molecular signatures might be used to classify idio-
pathic diseases. Alternatively, our findings may simply
Postn 4.1 3.1 5.8 7.1 4.8 3.9 2 2.8 -2.2
Tfrc -12.3 10 1.8 -1.6 -1.7 -1.5
Trp53inp1 4.3 1.5
Extracellular matrix morphology
Aspn 2.6 1.6 3 2 1.8 2.6 4.5
Cilp 3.8 5.4 2.8 1.9
Fbln2 1.7 1.5 3.2 2.1 1.6 1.6 2.2
Mfap5 3.1 1.5 3.8 2.9 1.8 -4.2
Other or unknown
Arrdc3 2.1 1.8
Dhrs7 -1.6 -1.5
Hs2st1 -2 1.8 -1.8
Kcnt2 2.2 -1.9 1.6
Klhl24 2.7 -3.1 1.6 -1.6
Obfc2a -2.1 -1.8 -1.7
Pcmtd2 2.1 -1.8 1.6 -3
Reep1 -2.8 -3.9 -2.5 -1.7
Rnase4 2 2.6 1.5 1.9
Trmt5 2.4 i 1.5
Tsfm -1.7 -3.6 -1.5
Zbtb44 2 -1.6 1.6
Zfp428 -2.2 1.5
FC = fold-change. Dash ("-") before number indicates down-regulation, compared to appropriate controls. A blank indicates that no significant 
alteration (fold change at least 1.5, p value ≤ 0.05) was observed. The asterisk indicates that a variant of MHC-β (MYH7B) was up-regulated. For 
PMAGE data, "i" and "d" indicate induction and down-regulation with 0 transcripts detected in either wild-type or αMHC403/+ mice, respectively. 
Idiop, Isch, AS, and Cong = idiopathic, ischemic, aortic stenosis, and congenital, respectively. "Drug" refers to angiotensin II treatment. (No gene 
alterations in common with ISO treatment were found for 3,5-diiodothyropropionic acid treated-rats.) Sh, MI, and AB = shunt, myocardial 
infarction, and aortic banding, respectively. RQ = αMHC403/+ mice, representing familial cardiac hypertrophy. Phys = physiological. Gene functions 
were obtained from Ingenuity pathway analysis software, supplemented with information obtained from the NCBI and Stanford SOURCE search 
databases. Some genes perform more than one function, but are only listed under one category.
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Table 6: Genes altered in human pathological cardiac hypertrophy that are recapitulated in animal models
Gene Human Animal Models
A SC o n gI d i o pI s c hD r u gR QA BM IS h S a l t E x e r c i s e
Pathological Phys
Adhesion and migration
ITGBL1 1.9 2.7 2.4 1.8
LTBP2 1.6 2.4 3.3 2.0 13.0
OMD 1.8 2.4 2.6 5.1
SERPINE2 2.6 1.5 1.8 1.7 2.8
THBS4 1.7 2.2 2.8 1.9 1.8 1.5
Cardiovascular functions
AOC3 1.5 1.6 2.2
APP 2.0 1.9 3.6 1.5 1.7 -1.6
ATP1A1 -1.7 -1.6 -1.9 d +/- 2.3 -5.3
CCL2 -2.9 -2.7 3.7 1.9 3.7 -2.3
CTGF 2.2 1.5 3.7 2.0 2.4 3.1 -3.6
EGFR -1.8 -1.5 2.9 -2.2
FN1 1.9 -1.6 -1.6 2.3 1.9 2.3 1.9 1.6 -1.7
M GCLM -2.1 -1.6 3.0 1.6
GSK3B -2.2 -1.7 -1.6 1.8
SERPINE1 -3.4 -3.6 1.6 1.8 3.4 1.9
SLC7A1 -2.0 -1.8 -1.6 -6.0
TGM2 -1.7 -1.7 1.9 1.5 -2.1
TIMP1 -1.9 -1.6 4.8 3.8 2.3 5.4 1.5 1.5
TIMP2 1.6 1.9 1.7 1.5 2.3
Cell growth/proliferation and survival
ACOX1 -1.6 2.1 -1.7 -5.5 1.7 -1.7
AMD1 -1.6 -2.0 -1.6 -2.6 -1.6 -1.6
CTSC -2.4 -2.1 -2.0 5.7 4.0 2.0 -1.8
DDX3X -1.6 -1.6 -2.6 2.5
KLF9 -2.0 -1.7 -3.9 -2.3 -1.6
OSMR -1.9 -1.5 3.6 1.5
PAPSS2 -1.8 -1.6 1.8 -1.5 1.5
PXDN 1.6 2.2 1.8 1.7
SULF1 1.7 2.2 1.9
TFRC -1.6 -1.7 -12.3 10.0 1.7 -2.8
Extracellular matrix morphology
ASPN 2.2 4.1 2.6 1.6 2.4 1.8
COL14A1 2.4 4.5 3.0 6.6
COL3A1 1.5 2.1 2.1 2.2 3.5 1.7 -4.5 -2.2
FBLN2 1.6 1.6 1.7 1.5 1.9 3.2
LUM 2.9 3.0 1.9 1.7 -2.2
MATN2 1.8 2.6 2.1
Immune response/modulation, inflammation, and stress response
DNAJA4 -2.4 -2.2 1.6 2.0 2.6 -2.9
FKBP4 -1.6 -1.5 -2.6 -1.6 -7.2 -2.0 -2.0
IFIT2 1.6 1.7 2.7 1.7
IFIT3 1.7 1.8 1.7 1.9
MGST1 -2.3 -2.4 2.0 2.0
Skeletal and muscular functions
CEBPD -2.4 -2.0 6.7 1.5 2.2 -2.0
COL1A1 1.5 1.7 2.1 +/- 2.6 2.6 1.7 -2.4 -1.5
COL1A2 1.9 1.7 2.1 2.7 2.5 3.1 -2.1 -2.2
FRZB 2.1 2.7 i 1.8 9.0
HSPB6 2.3 1.9 2.0
IGFBP5 1.6 2.0 2.3 4.5 1.5 -0.5
KBTBD10 -2.3 -1.8 1.8 1.8
Tissue morphology
BCL6 -2.2 -1.9 +/- -1.6
CFH 2.0 2.8 2.8 1.6 1.8 3.2
EGR1 -2.2 1.9 -3.3 0.1 1.8 1.6 -3.6BMC Physiology 2009, 9:23 http://www.biomedcentral.com/1472-6793/9/23
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reflect the notion that a common molecular signature
underlies many forms of endstage cardiac failure, irrespec-
tive of the etiology. A further complication is that some of
the changes in transcript expression may be secondary to
changes in cellular composition of cardiac tissue. How-
ever, we identified a core set of genes that characterize ani-
mal models and human cardiac disease, particularly
ischemia-induced cardiomyopathy (Table 6). This list rep-
resented several major cellular functions, including cell
adhesion and migration, cardiovascular-specific and mus-
cle-specific functions (e.g., cardiac tissue remodelling),
cellular growth, proliferation, and survival, extracellular
matrix morphology, immune response and inflamma-
tion, and stress response.One potential weakness in com-
paring human to animal models is that the human
samples may have been subjected to varying degrees of
warm ischemia during collection and processing, whereas
the animal models were probably collected under more
controlled circumstances. There are nonetheless some
interesting findings in the results obtained from compar-
ing the various animal model and human cardiac disease
gene expression profiles, as shown in Fig. 7. First, as might
be expected, the genetic expression profile from murine
exercised hearts is strikingly dissimilar from any of the
expression profiles from either the human diseased hearts
or hearts obtained from murine models of human dis-
ease. Secondly, the murine cardiac disease models that do
not have a readily recognizable human disease analog
(that is, animals treated with high salt, 3,5-diiodothyro-
propionic acid, and angiotensin II) cluster together, and
are not particularly similar to the human disease models.
Finally, the murine expression profile for animals treated
with aortic banding is very similar to the one obtained
from humans with aortic stenosis; these physiologic proc-
esses would be expected to be very similar, and the
extreme similarity in the gene expression profiles for these
conditions strongly supports the notion that microarray
genetic profile analysis can be used to determine the faith-
fulness of animal models in replicating human disease.
Conclusion
We characterized the transcription profile of mouse hearts
exposed to isoproterenol, a convenient, reproducible, and
rapid model of cardiac hypertrophy. We also indentified
the animal model and human cardiac disease transcrip-
tomes that most closely resemble ISO-treatment: myocar-
dial infarction and mutation of αMHC in mice and
ischemia-induced cadiomyopathy. We further identified a
core set of genes that might represent a universal maladap-
tive cardiac response to stress and provide individual gene
candidates for further investigation.
Methods
Animal models of cardiac hypertrophy
Eight-week old male C57BL/6 mice were purchased from
the Jackson Laboratory and housed in the Animal facility
at University of Texas Southwestern Medical Center
(UTSW), Dallas, TX, in accordance with the standards set
forth in the Guide for the Care and Use of Laboratory Animals
(NIH Publication No. 85-23, revised 1996). All experimen-
tal procedures for this study were approved by the Institu-
tional Animal Care and Use Committee at UTSW.
Pathological cardiac hypertrophy was investigated using
the isoproterenol-induced subacute myocardial injury
FLNC 1.5 -2.1 -1.8 1.6 1.6 -2.7
PRNP -2.0 -1.6 1.7 2.2
TXNRD1 -1.5 -2.0 1.6 1.9 -1.8
Other or Unknown
ART3 -1.8 -1.6 -1.6 -9.5 1.7
CCDC80 1.6 2.1 2.1 1.7 2.8 -6.3
FNDC1 2.0 3.4 2.2 5.0
HMGB2 1.6 1.6 2.1 3.0
ITIH5 1.6 2.0 2.2
KCND3 -1.8 -1.7 -1.7
LDB3 1.6 1.7 -1.9 11.0 1.6 1.8
LYPLA1 -2.1 -1.8 -2.9 0.3
SLC40A1 1.6 2.1 2.1 1.5 -1.7
SYNPO2L 1.6 2.0 2.2
TAF9B -1.7 -1.5 -1.7 2.0
FC = fold-change. Dash ("-") before number indicates down-regulation, compared to appropriate controls. A blank indicates that no significant 
alteration (fold change at least 1.5, p value ≤ 0.05) was observed. For PMAGE data, "i" and "d" indicate induction and down-regulation with 0 
transcripts detected in either wild-type or αMHC403/+ mice, respectively. Where genes that were represented by more than one polony (analogous 
to a probe set) conflicted in direction (one or more up-regulated sequence tags and one or down-regulated sequence tags representing the same 
gene), "+/-" is used in place of a FC value. Idiop, Isch, AS, and Cong = idiopathic, ischemic, aortic stenosis, and congenital, respectively. "Drug" refers 
to angiotensin II, 3,5-diiodothyropropionic acid, or isoproterenol treatment. Sh, MI, and AB = shunt, myocardial infarction, and aortic banding, 
respectively. RQ = αMHC403/+ mice, representing familial cardiac hypertrophy. Phys = physiological. Gene functions were obtained from Ingenuity 
pathway analysis software, supplemented with information obtained from the NCBI and Stanford SOURCE search databases. Some genes perform 
more than one function, but are only listed under one category.
Table 6: Genes altered in human pathological cardiac hypertrophy that are recapitulated in animal models (Continued)BMC Physiology 2009, 9:23 http://www.biomedcentral.com/1472-6793/9/23
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model as previously described [28]. Briefly, animals were
anesthetized with 1.5% isoflurane (Smiths Medical PM,
Waukesha, WI) in 98.5% oxygen and a 1 cm incision
made on the back of each animal between the shoulder
blades. An Alzet 1007D micro-osmotic pump (DURECT
Corporation, Cupertino, CA) containing isoproterenol
(ISO, Sigma-Aldrich, St. Louis, MO), at 40 mg.kg-1.d-1, dis-
solved in 0.9% NaCl was inserted into the infrascapular
subcutaneous tissue and the incision sutured. After 10
days of ISO administration, mice were sacrificed, and left
Connective tissue associated signalling network common to various cardiac hypertrophy animal models and human cardiac dis- ease Figure 6
Connective tissue associated signalling network common to various cardiac hypertrophy animal models and 
human cardiac disease. Ingenuity Pathway Analysis software was used to identify a signalling network associated with con-
nective tissue disease, overlaid with average expression data common to various animal models of cardiac hypertrophy and 
human cardiac diseases. Pathway Builder was then used to create a signalling pathway, based on the Ingenuity signalling net-
work, Biocarta's pathway database, and literature-based associations. TGF-β, which was not identified using microarrays but 
might nonetheless play a non-transcriptional role in heart disease, is shown as a plausible commonly activated pathway in the 
human failing heart and various animal models of cardiac hypertrophy. Also shown are the various extracellular matrix proteins 
that were transcriptionally up-regulated in animal models and human disease, based on microarrays. Signalling pathways associ-
ated with commonly down-regulated transcripts (e.g., AT1-R and EGFR) are also shown.BMC Physiology 2009, 9:23 http://www.biomedcentral.com/1472-6793/9/23
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Hierarchical cluster of a pairwise similarity matrix and ontological analysis to identify relatedness between animal models and  human cardiac disease Figure 7
Hierarchical cluster of a pairwise similarity matrix and ontological analysis to identify relatedness between ani-
mal models and human cardiac disease. A similarity matrix was produced for each model or human disease type, with 
each pairwise comparison score calculated as the number of genes altered in the same direction (up-regulated or down-regu-
lated at least 1.5-fold on average) compared to the appropriate study controls. The resulting scores were log transformed and 
Z scores calculated before performing hierarchical clustering using CLUSFAVOR 6.0 software (A). Bright red represents the 
highest pairwise similarity scores, black represents median values, and bright green represents the lowest pairwise similarity 
values. Each gene list was also analyzed using Ingenuity Pathway Analysis software and function categories for each animal 
model and human heart failure type compared (B). Functional categories shown were significantly over-represented (B-H mul-
tiple hypothesis correction p value ≤ 0.05), and numbers represent the number of altered genes in that category.
Function  ISO RQ AB MI Sh Ang2 Dipta Salt Isch Idiop  AS Cong 
Disease 
Cancer 120 19 36 90 17 18 12 3  124 38 40 25
Hematological disease  91 4  10 39 7  14 11 -  16 5     5 
Inflammatory response  64 12 4  74 3  17 6  -  41 -  6  26
Immunological  disease  38 4  9  42 10 9  4 -  21 - 5 3 
Cardiovascular disease  22 4  11 104 7  15 7  8  23 8  9  5 
Physiological System Development (D) and Function (F)  
Hematological system D and F  81 14 6  68 8  20 12 -  30 28 10 - 
Tissue development  70 11 11 49 7  19 3  4  20 14 20 14
Immune cell trafficking  66 9  2  58 -  15 8  -  20 21 5  - 
Cardiovascular system D and F  52 18 15 59 4  14 8  13 23 -  22 12
Connective tissue D and F  51 4  12 38 7  11 5  4  23 10 15 4 
Molecular and Cellular Functions 
Cellular growth and proliferation  213 -  17 112 13 18 7  6  29 15 29 8 
Cell death  185 -  8  53 12 18 9  2  82 25 29 12
Cellular movement  147 22 8  101 5  16 5  2  68 14 22 8 
Post-translational modification  57 2  -  29 1  1  -  -  17 7  2  2 
Cell-cell signaling/interaction  90 9  15 74 6  20 12 2  58  18 17 2 
Overlap -  12% 16% 68% 11% 22% 11% 9% 48% 16% 19% 13%
A
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ventricles were collected and processed for subsequent
assays.
Experimental physiological cardiac hypertrophy was
induced via exercise, as previously described [29]. Briefly,
mice were placed in buckets of pre-warmed water main-
tained at ~30°C with low-watt heat lamps and allowed to
swim for 90 minutes twice daily. At the beginning of the
experiment, mice were acclimated to the exercise routine
gradually, beginning with 10 minutes twice daily and
increasing in increments of 10 minutes per day, until 90
minutes was obtained. After 8 weeks of swimming, mice
were sacrificed and heart samples (left ventricles unless
otherwise stated) collected and processed for each assay.
Sedentary mice confined to cages served as negative con-
trols.
Histology
Hearts were excised from mice following euthanasia,
grossly trimmed in frontal orientation, blotted free of
excess blood and embedded in Tissue Freezing Medium
(Triangle Biomedical Sciences, Durham, NC). Rapid freez-
ing of embeds was achieved by partial immersion in liq-
uid-nitrogen-supercooled isopentane prior to storage at -
80°C. At a later time, embeds were equilibrated to -24°C
and sectioned on a Leica CM3000 cryostat (Wetzlar, Ger-
many). Eight-micron slices were adhered to silanated slide
glass (Superfrost Plus, Fisher Scientific, Pittsburg, PA) and
air-dried. Resulting sections were stained with routine
hematoxylin and eosin (H&E) for histopathological anal-
ysis or with Masson trichrome to assess fibrosis. In order
to assess apoptosis, TUNEL (TdT-mediated dUTP nick end
labeling) assays were performed using the DeadEnd
Fluorometric TUNEL System, as described by the manu-
facturer (Promega Corporation, Madison, WI). Specimens
were photomicrographed in bright field on a Leica
DM2000 microscope (Wetzlar, Germany), equipped with
an Optronics Microfire CCD camera (Goleta, CA). Image
acquisition was conducted using Optronics PictureFrame
2.0 software (Goleta, CA) and morphometric analysis was
conducted using Image J 1.38w software (NIH, Bethesda,
MD) for Macintosh computers.
Microarrays
Microarray sample preparation and analysis was per-
formed as previously described. Briefly, total RNA from
left ventricles of experimental animals was isolated using
TRIzol Reagent (Invitrogen Corporation, Carlsbad, CA)
per manufacturer's instructions and purified by phenol-
chloroform extraction and ethanol precipitation. RNA (20
μg) was further processed and hybridized to the Gene-
Chip Mouse Genome 430 2.0 Array (Affymetrix, Santa
Clara, CA) by the Microarray Core Facility at University of
Texas Southwestern Medical Center per manufacturer's
instructions. Data were analyzed using GeneSifter (VizX
Labs, Seattle, WA) and Spotfire DecisionSite 9.0 (Spotfire,
Inc., Somerville, MA). Briefly, data were normalized using
robust-multi average (RMA) method, and signals for each
group were averaged before performing Student's t test
with Benjamini and Hochberg correction and pairwise
comparisons for sedentary mice versus mice that received
ISO treatment or were exercised. Genes were considered as
altered if the folds-change was at least 1.5 and adjusted p
value ≤ 0.05. Consistency was also expected, which was
assessed by performing all possible pairwise comparisons
of individual samples. A fold-change of at least 1.5 was
expected for each replicate comparison (e.g., sedentary
mouse 1 versus swimming mouse 3), and this alteration
was expected to be at least 50% greater than the fold-
change derived from comparison of any two replicate
samples (e.g., sedentary mouse 1 versus sedentary mouse
2). This effectively eliminated differences that might arise
as a result of natural biological variation between mice.
Raw and processed data (a total of 9 arrays) were depos-
ited in the Gene Expression Omnibus (GEO) online http:/
/www.ncbi.nlm.nih.gov/geo database (Accession
GSE18801).
For comparison of our gene expression results to previous
studies, raw microarray data (CEL or text files) from mice
or rats with pathological or physiological cardiac hyper-
trophy induced by a variety of methods (details provided
in Table 3), were downloaded from Gene Expression
Omnibus http://www.ncbi.nlm.nih.gov/geo/. Gene
expression data from autopsied human hearts and failing
hearts collected during heart transplant surgeries were
also obtained from Cardiogenomics PGA [19]. Raw data
were RMA normalized using GeneSifter (or assumed to
already be normalized if only text files were provided) and
Student's t test and pairwise comparisons subsequently
performed using the appropriate included controls for
each data set. A fold-change of 1.5 or greater and p value
≤ 0.05 were considered as altered. The results from two
additional studies [16,17] for which raw array data were
unavailable were also included, using the reported gene
lists provided in the publication or as supplementary
material. Likewise, supplementary pre-processed data
(i.e., analyzed by original study researchers) from a study
using a novel approach (polony multiplex analysis of
gene expression, or PMAGE), which is designed to achieve
a much higher level of sensitivity than traditional gene
expression microarrays, was included. PMAGE data were
filtered based on average fold-difference (= 1.5) in order
to make the data comparable to microarray-based results.
However, only 10 potentially relevant genes were
excluded due to this additional criterion.
To link our study results (i.e., gene expression profiles of
ISO-treated and exercised mice) to results obtained from
the various other animal and human studies, a perl scriptBMC Physiology 2009, 9:23 http://www.biomedcentral.com/1472-6793/9/23
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was written to match genes across the various lists by
Accession number (for same species results) or gene sym-
bol (for inter-species results comparisons). If neither the
Accession number nor gene symbol matched perfectly,
then the gene descriptions were compared and same iden-
tify was considered if the names differed by nor more than
25%. If the ISO or swim results contained more than one
match for a single data point in a published study, only
the top three matches were recorded, with the best match
ordered first. This perl script was later modified to com-
pute averages for the multiple matches. This method
would be expected to fail to indentify some homologous
genes in which there are name designation differences
between species (e.g., the mouse version of human IL-8 is
referred to as KC or GRO). However, our intention was to
greatly minimize false positive and thus compare only
those genes that were truly the same between the various
data sets. To ensure that this was indeed the case, all final
genes lists representing overlap between study results were
also manually examined and any genes that were compu-
tationally misidentified subsequently removed.
Similarity matrix
To produce a similarity matrix, average fold change was
calculated for all animal model and human disease sam-
ples, compared to its appropriate control after normaliza-
tion (e.g. ischemic heart compared to non-diseased
autopsied heart). The two studies for which raw data were
unavailable were excluded (all samples listed in Table 3).
Statistical tests were not applied, but an alteration was
only considered if the magnitude of change was at least
1.5-fold. A perl script was written to combine the resulting
data for the ~2,300 genes that were represented on all
arrays using the official gene symbol as the criteria for
matching the genes across platforms and species. For
genes represented more than once on an array, the altera-
tion with the highest magnitude was recorded. The fold-
changes for the various similar sample sets (e.g., exercised
rodents) were averaged and a simple similarity scoring
scheme applied based on the numbers of genes with
same-direction alteration (fold change at least 1.5)
between each pairwise disease condition comparison.
These scores were then log transformed and converted to
Z scores and the resulting values clustered.
Hierarchical clustering
Hierarchical clustering of genes was performed using
Cluster/Treeview (Eisenlab, http://rana.lbl.gov/eisen/).
For comparison for the two cardiac hypertrophy models
used in this study (ISO-treated and swimming mice com-
pared to sedentary controls), normalized signal values
were used for clustering after Z score transformation. The
similarity matrix was clustered using normalized pairwise
scores as described above using CLUSFAVOR 6.0 (Baylor
College of Medicine, Houston, TX).
Real-time reverse transcriptase polymerase chain reaction 
(RT-PCR)
Real-time reverse transcriptase (RT)-polymerase chain
reaction (PCR) was performed in the iCycler iQ (Bio-Rad,
Hercules, CA) using SYBR Green I dye (QIAGEN, Valen-
cia, CA), as previously described [27]. Briefly, each 25-μl
reaction contained 100 ng of RNA, 2.5 μl of primers
(Quantitect Primer Assays; QIAGEN), 12.5 μlof SYBR
Green PCR master mix and 0.25 μl of reverse tran-
scriptase. Negative controls containing water instead of
RNA were concomitantly run to confirm that the samples
were not cross-contaminated. Targets were normalized to
reactions performed using Quantitect GAPDH primers
(QIAGEN), and fold change was determined using the
comparative threshold method [30].
Statistical Analysis
Values presented are expressed as mean ± S.E.M. All com-
parisons between groups were performed using a one-
tailed Student's t test or ANOVA. Differences were consid-
ered statistically significant for p < 0.05.
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